| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other (expense) income, net | -3,289 | -2,494 | - | 5,451 |
| Net loss | -60,715 | -71,847 | - | -84,126 |
| Unrealized gain on marketable securities | - | - | - | 1,188 |
| Comprehensive income (loss), net of tax, attributable to parent | - | - | - | -82,938 |
| Earnings per share, basic, total | -0.7 | -0.83 | -0.98 | -0.98 |
| Earnings per share, diluted, total | -0.7 | -0.83 | -0.98 | -0.98 |
| Weighted average number of shares outstanding, basic, total | 86,620,992 | 86,337,237 | 86,171,889 | 85,433,569 |
| Weighted-average number of common shares used to compute net loss per share attributable to common stockholdersdiluted | 86,620,992 | 86,337,237 | 86,171,889 | 85,433,569 |
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)